5–11 Dual Treatment and Diagnosis Role Played by Simultaneous Emission of β- and γ-rays — Production of Highly Purified Lutetium-177 for Radioimmunotherapy —




Fig.5-29 Treatment and diagnosis of cancer by a ¹⁷⁷Lu-labeled antibody

¹⁷⁷Lu is bound to an antibody through the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). The ¹⁷⁷Lu-labeled antibody administrated within the body binds to an antigen that is specifically expressed on a cancer cell. During treatment, *β*-rays emitted from ¹⁷⁷Lu kill the cancer cells. Simultaneously, diagnostic imaging to investigate the biodistribution in the body can be performed by measuring *γ*-rays from outside.

At present, beta-emitting radionuclides are used for cancer treatment. Lutetium-177 (¹⁷⁷Lu) is regarded as a promising novel radionuclide because it emits not only β -rays but also γ -rays. By measurement of the γ -rays from outside of the body, diagnostic imaging to investigate the biodistribution within the body can be performed (Fig.5-29).

Fig.5-29 shows a schematic diagram of radioimmunotherapy. ¹⁷⁷Lu is transported to a cancer cell by the antibody, which binds to an antigen that is specifically expressed on the cancer cell. By this therapy, if the purity of ¹⁷⁷Lu for the whole Lu isotope is low, the amount of ¹⁷⁷Lu transported to the cancer cell is reduced. Consequently, the therapeutic effect of ¹⁷⁷Lu upon the cancer cell is reduced. Two methods have been proposed to produce high purity ¹⁷⁷Lu. One is the direct method via the ¹⁷⁶Lu (n, γ) ¹⁷⁷Lu reaction. In this method, stable lutetium (176Lu) is irradiated at reactors in Europe and America with large amounts of neutron-generation over a limited area. The other is the indirect method via the ¹⁷⁶Yb (n, γ) ¹⁷⁷Yb (half-life: 1.91 h) \rightarrow ¹⁷⁷Lu reaction. In this method, stable ytterbium (176Yb) is irradiated at reactors throughout the world with a low quantity of neutrons, and ¹⁷⁷Lu is separated from Yb. Therefore, to produce high-purity ¹⁷⁷Lu with the indirect method, various separation methods of ¹⁷⁷Lu from Yb have been investigated in many countries.

We have developed a method for completely separating ¹⁷⁷Lu from Yb using a reversed-phase silica gel column




Fig.5-30 Separation of ¹⁷⁷Lu from neutron-irradiated Yb

In the conventional method (a) that we have developed, the labeling yield of the ¹⁷⁷Lu-labeled antibody was < 5%, owing to inhibition by Ca, Fe, and Zn included in final ¹⁷⁷Lu product. In the novel method (b), the Ca, Fe, and Zn were eliminated by both purification of eluent and addition of an anion exchange. Consequently, the labeling yield of the ¹⁷⁷Lu-labeled antibody increased up to 88%.

(Fig.5-30(a)) and have synthesized ¹⁷⁷Lu-labeled antibodies using the ¹⁷⁷Lu produced by our separation method. However, the labeling yield was < 5%. From the results of elemental analysis, it was found that calcium (Ca), iron (Fe), and zinc (Zn) were included in the final ¹⁷⁷Lu product, and that these metallic elements competitively inhibited the complexation between ¹⁷⁷Lu and 1,4,7,10-tetraazacyclododecane-1,4,7,10 -tetraacetic acid. Consequently, the labeling yield of ¹⁷⁷Lulabeled antibody decreased. It was also found that these metallic elements were included as impurities in the regents of both 2-hydroxyisobutyric acid (2-HIBA) and 1-octanesulfonicacid sodium salt (1-OS), eluents of the reversed-phase silicagel column. Therefore, the eluents of 2-HIBA and 1-OS were purified by cation-exchange and chelating-ion-exchange columns in advance, respectively. Furthermore, an anion exchange was added as a final purification step (Fig.5-30(b)). The concentrations of Ca, Fe, and Zn in the final ¹⁷⁷Lu product were reduced from 87, 340, and 77 ppb to 13, 18, and 9 ppb, respectively, and the labeling yield of the ¹⁷⁷Lu-labeled antibody increased up to 88%. Consequently, we successfully produced highly purified ¹⁷⁷Lu capable of being applied to radioimmunotherapy.

If the highly purified ¹⁷⁷Lu can be produced using our method all over the world, radioimmunotherapy with ¹⁷⁷Lu will spread widely.

Reference

Watanabe, S. et al., Production of Highly Purified No-Carrier-Added ¹⁷⁷Lu for Radioimmunotherapy, Journal of Radioanalytical and Nuclear Chemistry, vol.303, issue 1, 2015, p.935-940.